Publications NKT Science Publications Presentations and Publications November, 2024 A New Approach to Inflammatory Diseases Marc Hertz PhD, Chief Executive Officer of GRI BioNovember 21, 2024, Boston, MA November, 2024 8th Annual Antifibrotic Drug Development (AFDD) Summit Involvement Of Type 1 Invariant Natural Killer T Cells In Driving Lung Fibrosis October, 2024 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) Involvement Of Type 1 Invariant Natural Killer T Cells In Driving Lung Fibrosis July, 2024 American Journal of Respiratory and Critical Care Medicine Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis May, 2024 14th International Congress on Autoimmunity 2024 ATS International Conference October, 2023 7th Antifibrotic Drug Development Summit October, 2023 Altered NKT cell populations in the airways of patients with IPF September, 2023 Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis May, 2020 Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease. February, 2019American Journal of Physiology Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. November, 2018 Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. September, 2018Frontiers in Immunology Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. February, 2018Gastroenterology Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. February, 2017 Type II NKT Cells and Their Emerging Role in Health and Disease. March, 2016Cellular and Molecular Immunology Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. April, 2015Heptology Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Heptology; April, 2015 November, 2014 Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. September, 2013 NKT-cell subsets: promoters and protectors in inflammatory liver disease. July, 2007Journal of Clinical Investigation Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. April, 2004Journal of Experimental Medicine Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. Our Science Our Pipeline Our Team
